| 0 (0%) | 11-11 17:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.94 | 1-year : | 1.07 |
| Resists | First : | 0.8 | Second : | 0.92 |
| Pivot price | 0.69  |
|||
| Supports | First : | 0.61 | Second : | 0.51 |
| MAs | MA(5) : | 0.66  |
MA(20) : | 0.69 |
| MA(100) : | 1.15 |
MA(250) : | 2.62 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.6 |
D(3) : | 23.7 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 11.48 | Low : | 0.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BVXV ] has closed above bottom band by 39.1%. Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.71 |
| Low: | 0.65 - 0.66 | 0.66 - 0.66 |
| Close: | 0.66 - 0.67 | 0.67 - 0.67 |
Tue, 11 Jul 2023
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. - Yahoo Finance
Tue, 30 May 2023
BVXV: Developing anti-IL-17 NanoAb - Zacks Small Cap Research
Tue, 06 Dec 2022
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board - Yahoo Finance
Sun, 25 Oct 2020
Biondvax plunges on failed universal flu vaccine trial - Globes - Israel Business News
Fri, 23 Oct 2020
BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate - BioSpace
Wed, 17 Jul 2019
Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax - CTech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 20 (%) |
| Held by Institutions | 10.6 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -2.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.97 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | 0 |
| Price to Book value | -0.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|